Drugs / ISA104
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT05841095 Comparator | Aug 2023 → Dec 2026 expected | chronic hepatitis B virus infection | Erasmus Medical Center | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISA104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05841095 ↗ |
| Modality | Vaccine | “SLP vaccine” NCT05841095 ↗ |